Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants

NCT03934541 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: MPER-656 Liposome Vaccine
BIOLOGICAL: Placebo for MPER-656 Liposome Vaccine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)